<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00320671</url>
  </required_header>
  <id_info>
    <org_study_id>R01MH060004-02</org_study_id>
    <secondary_id>R01MH060004-02</secondary_id>
    <nct_id>NCT00320671</nct_id>
  </id_info>
  <brief_title>Comparison of Aripiprazole and Risperidone for the Treatment of People With First-Episode Psychosis</brief_title>
  <official_title>Preventing Morbidity in First Episode Schizophrenia, Part II</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwell Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Northwell Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This 52 week long study evaluates the effectiveness of aripiprazole versus risperidone in
      treating people with first-episode schizophrenia. Patients who do not improve with these
      medications receive clozapine as their third medication trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Schizophrenia is a severely disabling brain disorder. People with schizophrenia often
      experience hallucinations, delusions, thought disorders, and movement disorders. Medications
      are available to alleviate the symptoms of schizophrenia, but many cause undesirable side
      effects. For example, two early second generation antipsychotics, olanzapine and risperidone,
      have been shown to be effective in treating schizophrenia symptoms, but cause rapid,
      substantial weight gain. There is a lower risk of such side effects with newer second
      generation antipsychotics, such as aripiprazole. Little is known, however, about the
      effectiveness of these newer medications in treating people with first-episode schizophrenia.
      This study will evaluate the effectiveness of aripiprazole versus risperidone for the
      treatment of first-episode schizophrenia.

      Participants in this double-blind study will be randomly assigned to receive either
      aripiprazole or risperidone for 12 weeks. Subjects who do not meet response criteria will be
      continued on their initial blinded antipsychotic for an additional 4 weeks for a total length
      of 16 weeks of treatment. Subjects who meet response criteria by week 16 will continue on
      their successful blinded medication for their remaining time in study. Patients who do not
      respond will be treated with the other medication (aripiprazole or risperidone) that they did
      not receive during the first 16 weeks of the study. The second antipsychotic trial will last
      16 weeks. Patients who respond during the switch phase will be continued on their successful
      medication during their remaining time in the study. Patients who do not respond to the
      second medication trial will then be treated with open-label clozapine for 20 weeks. Safety
      monitoring for clozapine-treated subjects will follow the established procedures for
      multi-episode patients (e.g . weekly complete blood count (CBC) monitoring). The total length
      of patient participation is 52 weeks.

      During the longitudinal follow-up phase, subjects may be prescribed open-label sodium
      valproate for manic symptoms and open-label sertraline for symptoms of depression or anxiety
      empirically responsive to (Selective serotonin reuptake inhibitor)SSRI treatment.
      Additionally, all participants will take part in a Healthy Lifestyles program aimed at
      preventing weight gain. The Healthy Lifestyles program will provide psycho-education,
      supportive psychotherapy, and medication adherence counseling. At each visit, treatment and
      metabolic outcomes will be assessed. Participants will meet with both a psychiatrist, who
      will evaluate progress and medication dosage, and a social worker, who will administer the
      Healthy Lifestyles Program. Upon completion of the study, participants will receive follow-up
      care from clinical staff members who were not part of the research team.

      For information on a related study, please follow this link:

      http://clinicaltrials.gov/show/NCT00000374
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2005</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants That Responded to Treatment</measure>
    <time_frame>this outcome was assessed throughout the study.</time_frame>
    <description>Brief Psychiatric Rating Scale-Anchored (BPRS-A) 4 items on this scale were examined to determine subjects responder status: Items 4. Conceptual Disorganization 8. Grandiosity 12. Hallucinations and 15. Unusual Thought Content. Scores range from-7 (not assessed) to 7 (very severe) Subjects with scores of 3 or less on all 4 items for 2 consecutive visits are deemed responders, subjects with 4 or greater and any of the aforementioned items for 2 consecutive study visits are non responders. Additionally, the subjects response on the Clinical Global Impressions Scale. A Clinical Global Improvement CGI) rating of much or very much improved on 2 consecutive ratings were deemed a responder. Percentages and confidence intervals were used to report response outcome. Response status was assessed throughout the duration of the study; a participant can be deemed a responder any time between weeks 1-week 12. The possible range for this outcome is a score of 4 to 28</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">198</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Participants will take aripiprazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will take aripiprazole</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Participants will take risperidone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will take risperidone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aripiprazole</intervention_name>
    <description>The dosage for aripiprazole will be 5 mg to 30 mg per day in capsule form. The dose of aripiprazole will be based on the participant's clinical improvement and side effects, which will be evaluated weekly for the first 4 weeks and then every 2 weeks until the 12th week and then monthly until study end.</description>
    <arm_group_label>Participants will take aripiprazole</arm_group_label>
    <other_name>Abilify</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Risperidone</intervention_name>
    <description>The dosage for risperidone will be 1 mg to 6 mg per day in capsule form. The dose of risperidone will be based on the participant's clinical improvement and side effects, which will be evaluated weekly for the first 4 weeks, then every 2 weeks until the 12th week, and then monthly until the study end.</description>
    <arm_group_label>Participants will take risperidone</arm_group_label>
    <other_name>Risperdal</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Current Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) diagnosis of
             schizophrenia, schizophreniform disorder, schizoaffective disorder, or similar
             psychotic disorder not otherwise specified, as assessed using the Structured Clinical
             Interview for Axis I DSM-IV Disorders (SCID-I/P)

          -  History of previous antipsychotic medication treatment for a duration of 2 weeks or
             less

          -  Current positive symptoms rated 4 (moderate) or more on one or more of the following
             Brief Psychiatric Rating Scale (BPRS-A) items: conceptual disorganization;
             grandiosity; hallucinatory behavior; or unusual thought content

          -  Agrees to use an effective form of contraception

        Exclusion Criteria:

          -  Any serious neurological or endocrine disorder, or any medical condition or treatment
             known to affect the brain

          -  Any current medical condition that requires treatment with a medication with
             psychotropic effects

          -  At significant risk for suicidal or homicidal behavior

          -  Cognitive or language limitations, or any other factor that would interfere with a
             participant's ability to provide informed consent or safely participate in study
             procedures

          -  Diagnosis of diabetes, defined as a fasting plasma glucose level of at least 126
             mg/dL, or metabolic syndrome, defined as three or more of the following: high blood
             pressure (greater than 135/85 mmHg); truncal obesity (having a waist circumference
             greater than 40 inches for men and greater than 35 inches for women); elevated fasting
             glucose (greater than 110 mg/dL); low HDL-cholesterol (less than 40 mg/dL for men and
             less than 50 mg/dL for women); or elevated triglycerides (defined as greater than 150
             mg/dL)

          -  Requires treatment with an antidepressant or mood stabilizing medication

          -  Meets DSM-IV criteria for a current substance-induced psychotic disorder, a psychotic
             disorder due to a general medical condition, delusional disorder, brief psychotic
             disorder, shared psychotic disorder, or a mood disorder (major depression or bipolar)
             with psychotic features

          -  Any medical conditions that would make treatment with risperidone or aripiprazole
             medically inadvisable
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Delbert Robinson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The North Shore-Long Island Jewish Health System</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Zucker Hillside Hospital</name>
      <address>
        <city>Glen Oaks</city>
        <state>New York</state>
        <zip>11004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Canada</country>
  </removed_countries>
  <link>
    <url>http://schizophreniabulletin.oxfordjournals.org/content/41/6/1227.long</url>
    <description>Aripiprazole and Risperidone for the Acute Treatment of First-Episode Schizophrenia</description>
  </link>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 1, 2006</study_first_submitted>
  <study_first_submitted_qc>May 1, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 3, 2006</study_first_posted>
  <results_first_submitted>March 22, 2016</results_first_submitted>
  <results_first_submitted_qc>July 19, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 31, 2016</results_first_posted>
  <last_update_submitted>September 7, 2016</last_update_submitted>
  <last_update_submitted_qc>September 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwell Health</investigator_affiliation>
    <investigator_full_name>Delbert Robinson</investigator_full_name>
    <investigator_title>Professor of Psychiatry and Molecular Medicine</investigator_title>
  </responsible_party>
  <keyword>First-episode</keyword>
  <keyword>Schizoaffective Disorder</keyword>
  <keyword>Schizophreniform Disorder</keyword>
  <keyword>Psychotic Disorder Not Otherwise Specified NOS</keyword>
  <keyword>Aripiprazole</keyword>
  <keyword>Clozapine</keyword>
  <keyword>Risperidone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Risperidone</mesh_term>
    <mesh_term>Aripiprazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Participants Will Take Aripiprazole Arm 1</title>
          <description>-102 were allocated to Arm 1.</description>
        </group>
        <group group_id="P2">
          <title>Participants Will Take Risperidone Arm 2</title>
          <description>-96 participants were randomized to to Arm 2</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="102"/>
                <participants group_id="P2" count="96"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="69"/>
                <participants group_id="P2" count="58"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="38"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Participants Will Take Aripiprazole</title>
          <description>Participants will take aripiprazole
Aripiprazole: The dosage for aripiprazole will be 5 mg to 30 mg per day in capsule form. The dose of aripiprazole will be based on the participant's clinical improvement and side effects, which will be evaluated weekly for the first 4 weeks and then every 2 weeks until the 12th week and then monthly until study end.</description>
        </group>
        <group group_id="B2">
          <title>Participants Will Take Risperidone</title>
          <description>Participants will take risperidone
Risperidone: The dosage for risperidone will be 1 mg to 6 mg per day in capsule form. The dose of risperidone will be based on the participant's clinical improvement and side effects, which will be evaluated weekly for the first 4 weeks, then every 2 weeks until the 12th week, and then monthly until the study end.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="102"/>
            <count group_id="B2" value="96"/>
            <count group_id="B3" value="198"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74"/>
                    <measurement group_id="B2" value="68"/>
                    <measurement group_id="B3" value="142"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73"/>
                    <measurement group_id="B2" value="70"/>
                    <measurement group_id="B3" value="143"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>African-American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other/Mixed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="102"/>
                    <measurement group_id="B2" value="96"/>
                    <measurement group_id="B3" value="198"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Structured Clinical Interview for DSM-IV Axis I Disorders</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>psychosis NOS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Schizoaffective Disorder</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Schizophrenia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72"/>
                    <measurement group_id="B2" value="59"/>
                    <measurement group_id="B3" value="131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Schizophreniform Disorder</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BPRS-A</title>
          <description>Brief Psychiatric Rating Scale-Anchored (BPRS-A) 4 items on this scale were examined to determine subjects responder status: Items 4. Conceptual Disorganization 8. Grandiosity 12. Hallucinations and 15. Unusual Thought Content.
Only subjects who responded with a 4 or greater on one at least one of theses items were eligible to participate in the study. The scores can range from 0-28 with 28 being the most psychotic and 0 being absolutely no signs of psychosis.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14.66" lower_limit="4" upper_limit="28"/>
                    <measurement group_id="B2" value="14.42" lower_limit="4" upper_limit="28"/>
                    <measurement group_id="B3" value="14.54" lower_limit="4" upper_limit="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Scale for the Assessment of Negative</title>
          <description>The Scale for the Assessment of Negative Symptoms (SANS) This scale has 4 subscales Affective flattening, Alogia, Avolition Apathy, and Asociality-anhedonia. Score on these subscales range from 1 normal to 5 severe</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Affective flattening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.85" spread="0.09"/>
                    <measurement group_id="B2" value="1.74" spread=".09"/>
                    <measurement group_id="B3" value="1.795" spread=".09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alogia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.08" spread=".08"/>
                    <measurement group_id="B2" value="1.96" spread=".09"/>
                    <measurement group_id="B3" value="2.02" spread=".85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>avolition-apathy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.16" spread=".10"/>
                    <measurement group_id="B2" value="2.02" spread=".10"/>
                    <measurement group_id="B3" value="2.09" spread=".10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>asociality-anhedonia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.19" spread=".08"/>
                    <measurement group_id="B2" value="2.07" spread=".09"/>
                    <measurement group_id="B3" value="2.12" spread=".85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Metabolic Outcomes</title>
          <units>mg/dl</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Total Cholesterol Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="158.25" spread="3.15"/>
                    <measurement group_id="B2" value="157.01" spread="3.30"/>
                    <measurement group_id="B3" value="157.63" spread="3.225"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL cholesterol Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="86.37" spread="2.60"/>
                    <measurement group_id="B2" value="88.25" spread="2.77"/>
                    <measurement group_id="B3" value="87.31" spread="2.685"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL Cholesterol baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.99" spread="1.37"/>
                    <measurement group_id="B2" value="53.23" spread="1.40"/>
                    <measurement group_id="B3" value="54.61" spread="1.385"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="80.00" spread="4.48"/>
                    <measurement group_id="B2" value="77.41" spread="4.50"/>
                    <measurement group_id="B3" value="78.705" spread="4.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fasting glucose baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="85.06" spread="0.69"/>
                    <measurement group_id="B2" value="84.60" spread="0.89"/>
                    <measurement group_id="B3" value="84.83" spread=".79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>hollingshead- index of social position</title>
          <description>The Hollingshead is designed to measure social status of an individual based on educational and occupation. Scores for educational status range from 1 (Grad/Professional School) to a score of 7 ( &lt; than 7 yrs of formal education). For occupation scores range from 1 (high execs, major professionals) to 7 (unskilled employees). Social class scores are obtained for subjects and their self-reported head of household.
Social Status is based on the formula (Occupation score x 7)+(Education score x 4)-The lower the # the &gt; the social status. Social status scores range from 11 to 77.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Highest Educational Level</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.0" spread="1.4"/>
                    <measurement group_id="B2" value="3.8" spread="1.1"/>
                    <measurement group_id="B3" value="3.9" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social Class for subject</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.2" spread=".8"/>
                    <measurement group_id="B2" value="4.6" spread="3.4"/>
                    <measurement group_id="B3" value="4.4" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>social class for parent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.3" spread="1.3"/>
                    <measurement group_id="B2" value="3.5" spread="3.6"/>
                    <measurement group_id="B3" value="3.4" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Marital Status</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Never Married</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="92"/>
                    <measurement group_id="B2" value="90"/>
                    <measurement group_id="B3" value="182"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Married</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Remarried</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Divorced</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fasting insulin</title>
          <units>uU/ml</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12.39" spread="1.10"/>
                    <measurement group_id="B2" value="13.10" spread="1.38"/>
                    <measurement group_id="B3" value="12.745" spread="1.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prolactin Level Female</title>
          <description>The measure of dispersion selected is standard deviation; however, the actual number entered below is the STANDARD ERROR.</description>
          <units>ng/ml</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.84" spread="7.61"/>
                    <measurement group_id="B2" value="65.52" spread="12.88"/>
                    <measurement group_id="B3" value="63.68" spread="10.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prolactin Level Male</title>
          <description>The measure of dispersion selected is standard deviation; however, the actual number entered below is the STANDARD ERROR</description>
          <units>ng/ml</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.72" spread="3.05"/>
                    <measurement group_id="B2" value="31.50" spread="3.24"/>
                    <measurement group_id="B3" value="30.11" spread="3.145"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants That Responded to Treatment</title>
        <description>Brief Psychiatric Rating Scale-Anchored (BPRS-A) 4 items on this scale were examined to determine subjects responder status: Items 4. Conceptual Disorganization 8. Grandiosity 12. Hallucinations and 15. Unusual Thought Content. Scores range from-7 (not assessed) to 7 (very severe) Subjects with scores of 3 or less on all 4 items for 2 consecutive visits are deemed responders, subjects with 4 or greater and any of the aforementioned items for 2 consecutive study visits are non responders. Additionally, the subjects response on the Clinical Global Impressions Scale. A Clinical Global Improvement CGI) rating of much or very much improved on 2 consecutive ratings were deemed a responder. Percentages and confidence intervals were used to report response outcome. Response status was assessed throughout the duration of the study; a participant can be deemed a responder any time between weeks 1-week 12. The possible range for this outcome is a score of 4 to 28</description>
        <time_frame>this outcome was assessed throughout the study.</time_frame>
        <population>BPRS-A and CGI scores for each group were analysed to determine the percentage of participants that responded to apriprazole and risperidone. The threshold for significance was p=.05</population>
        <group_list>
          <group group_id="O1">
            <title>Percentage of Participants That Reposonded to Aripiprazole</title>
            <description>Aripiprazole: The dosage for aripiprazole will be 5 mg to 30 mg per day in capsule form. The dose of aripiprazole will be based on the participant's clinical improvement and side effects, which will be evaluated weekly for the first 4 weeks and then every 2 weeks until the 12th week and then monthly until study end.</description>
          </group>
          <group group_id="O2">
            <title>Percentage of Participants That Reposonded to Risperidone</title>
            <description>Risperidone: The dosage for risperidone will be 1 mg to 6 mg per day in capsule form. The dose of risperidone will be based on the participant's clinical improvement and side effects, which will be evaluated weekly for the first 4 weeks, then every 2 weeks until the 12th week, and then monthly until the study end.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants That Responded to Treatment</title>
          <description>Brief Psychiatric Rating Scale-Anchored (BPRS-A) 4 items on this scale were examined to determine subjects responder status: Items 4. Conceptual Disorganization 8. Grandiosity 12. Hallucinations and 15. Unusual Thought Content. Scores range from-7 (not assessed) to 7 (very severe) Subjects with scores of 3 or less on all 4 items for 2 consecutive visits are deemed responders, subjects with 4 or greater and any of the aforementioned items for 2 consecutive study visits are non responders. Additionally, the subjects response on the Clinical Global Impressions Scale. A Clinical Global Improvement CGI) rating of much or very much improved on 2 consecutive ratings were deemed a responder. Percentages and confidence intervals were used to report response outcome. Response status was assessed throughout the duration of the study; a participant can be deemed a responder any time between weeks 1-week 12. The possible range for this outcome is a score of 4 to 28</description>
          <population>BPRS-A and CGI scores for each group were analysed to determine the percentage of participants that responded to apriprazole and risperidone. The threshold for significance was p=.05</population>
          <units>percentage of response</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="96"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.8" lower_limit="50.8" upper_limit="74.8"/>
                    <measurement group_id="O2" value="56.8" lower_limit="43.9" upper_limit="69.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Equivalence Analysis</non_inferiority_desc>
            <p_value>.61</p_value>
            <method>Log Rank</method>
            <param_type>Cumulative Response Rates</param_type>
            <param_value>56.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>43.9</ci_lower_limit>
            <ci_upper_limit>69.9</ci_upper_limit>
            <estimate_desc>Only the subjects taking risperidone were analysed in this section</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Equivalence Analysis</non_inferiority_desc>
            <p_value>.61</p_value>
            <method>Log Rank</method>
            <param_type>Cumulative Response Rates</param_type>
            <param_value>62.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>50.8</ci_lower_limit>
            <ci_upper_limit>74.8</ci_upper_limit>
            <estimate_desc>Only subjects taking aripiprazole were analysed in this section</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were assessed throughout the duration of the study., up to 12 weeks. The only serious adverse event that was reported was subjects being admitted to the hospital. No other serious adverse occurred throughout the duration of the study.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Participants Will Take Aripiprazole</title>
          <description>Aripiprazole: The dosage for aripiprazole will be 5 mg to 30 mg per day in capsule form. The dose of aripiprazole will be based on the participant's clinical improvement and side effects, which will be evaluated weekly for the first 4 weeks and then every 2 weeks until the 12th week and then monthly until study end.</description>
        </group>
        <group group_id="E2">
          <title>Participants Will Take Risperidone</title>
          <description>Risperidone: The dosage for risperidone will be 1 mg to 6 mg per day in capsule form. The dose of risperidone will be based on the participant's clinical improvement and side effects, which will be evaluated weekly for the first 4 weeks, then every 2 weeks until the 12th week, and then monthly until the study end.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>hospitalization</sub_title>
                <description>subjects were admitted to the hospital</description>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="102"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Metabolic data only capture initial effects and may been impacted by Healthy Lifestyles program neg symptoms are only assessed in the initial context of pos symptoms and may not generalize to neg symptoms in the absence of pos symptoms.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Delbert Robinson MD</name_or_title>
      <organization>Northwell</organization>
      <phone>718.470.8195</phone>
      <email>drobinson@nshs.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

